Search Results 401-410 of 18022 for Alopecia

1. A Study to Evaluate the Effectiveness and Safety of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma and in Subjects with Clinical High-Risk Multiple Myeloma - Mayo Clinic

   due to prior treatments, excluding alopecia and Grade 2 neuropathy. Exclusion Criteria: The presence of any of the following will exclude a subject from ...

2. Psoriasis - Doctors and departments - Mayo Clinic

   ... Alopecia areata, Melasma, Vascular anomaly, Dermatitis, Morphea, Skin problems, Vulvar skin disorder, Breast skin change, Rosacea, Pigmentation disorder ...

3. A Phase 2 Study Of ONC206 In Advanced Pheochromocytoma And Paraganglioma - Mayo Clinic

   Has unresolved toxicities from previous locoregional, systemic, or any other therapies, defined as toxicities (other than Grade ≤2 neuropathy or alopecia) ...

4. Innovative Trial for Understanding the Impact of Targeted Therapies in NF2 - Mayo Clinic

   prior therapies (excluding alopecia, neuropathy, and nail changes). - Clinical laboratory values as specified below within 14 days before the first dose of

5. Pemigatinib to Treat Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations - Mayo Clinic

   Exception: alopecia. Current use of prohibited medication: Concomitant administration of potent CYP3A4 inhibitors and inducers and moderate CYP3A4 inducers ...

6. BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study - Mayo Clinic

   Skin disorders (e.g., vitiligo, psoriasis, or alopecia) not requiring systemic treatment; - Conditions not expected to recur in the absence of an external ...

7. Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy Or Plus Camizestrant In HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, Or PALB2m Advanced Breast Cancer - Mayo Clinic

   ... alopecia * Spinal cord compression, brain metastases, carcinomatous meningitis, or leptomeningeal disease * Evidence of active and uncontrolled hepatitis B ...

8. Klippel-Trenaunay syndrome - Doctors and departments - Mayo Clinic

   ... Alopecia areata, Diffuse capillary malformation with overgrowth, Vulvar skin disorder, Blue rubber bleb nevus syndrome, Vascular anomaly, Vascular ...

9. DAREON™-9: A Study To Test How Well Different Doses Of BI 764532 Are Tolerated By People With Small Cell Lung Cancer When Taken Together With A Single Agent Chemotherapy - Mayo Clinic

   Persistent toxicity from previous treatments that has not resolved to ≤ Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 (except for alopecia ...

10. A Study to Evaluate IMGN632 with Venetoclax and/or Azacitidine to Treat Patients with CD123-Positive Acute Myeloid Leukemia - Mayo Clinic

    Previous treatment-related toxicities must have resolved to Grade 1 or baseline (excluding alopecia). Total white blood cell count must be less than 25 × 10 ...